Search the Newsreel

What's Going On With Medipharm Labs Corp Stock Friday?

Ascendis Pharma Reports Solid Yorvipath Quarter; Yuviwel Off to Strong Start, RBC Says

Ascendis Pharma's (ASND) Q2 results showed a solid rebound for Yorvipath, while the early launch of Yuviwel in achondroplasia is progressing well, RBC Capital Markets said in a Thursday note.According to the note, Yorvipath revenue rose to 252 million euros ($291.8 million) from Silver …

Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day

Inovio Pharmaceuticals Inc. (INO) shares surged 21.10% to $1.09 on Friday, outperforming the broader market as the NASDAQ Composite Index and Dow Jones Industrial Average both experienced declines. This marked the fifth consecutive day of gains for Inovio's stock, despite a generally rough trading …

BridgeBio Pharma's Transition to Rare Disease 'Commercial Powerhouse' On Track, RBC Says

BridgeBio Pharma's (BBIO) transition into a rare disease "commercial powerhouse" is on track and poised to accelerate, RBC Capital Markets said in a Friday note.The company's Attruby drug is gaining traction in first-line treatment settings, while the market for the drug Silver Upgrade to …

Amneal Pharmaceuticals Director John Kiely Sells 50,000 Shares and Donates 10,000 Shares on August 13, 2026

John Kiely, a director at Amneal Pharmaceuticals (NASDAQ: AMRX), sold 50,000 shares of Class A Common Stock at an average price of $17.64 and donated 10,000 shares to a donor-advised fund on August 13, 2026. After these transactions, Kiely's direct ownership in the company …

NRx Pharmaceuticals nears FDA approval milestone amid expected quarterly loss and low revenue.

NRx Pharmaceuticals is anticipating a quarterly loss of $0.09 per share and revenue of $1.33 million, despite financial challenges. The company has made significant progress towards FDA approval for its preservative-free ketamine, with major regulatory risks addressed. NRx will discuss these developments and commercialization …

Nuvectis Pharma (NASDAQ:NVCT) Shares Gap Up - What's Next?

Nuvectis Pharma (NASDAQ:NVCT) shares gapped up before market open but then traded lower. The company missed its quarterly earnings expectations, reporting a wider loss than anticipated. Despite mixed analyst ratings, CEO Ron Bentsur and major shareholder Marlio Charles Mosseri recently purchased significant amounts of …

Amylyx Pharmaceuticals (AMLX) Is Down 7.1% After Wider Q2 Loss And Avexitide Phase III Update

Amylyx Pharmaceuticals reported a wider Q2 2026 net loss of US$43.42 million, though the loss per share improved. The company is advancing towards a pivotal Phase III data readout for avexitide in post-bariatric hypoglycemia, with potential commercialization targeted for 2027 if approved. This upcoming …

Latham Represents Zentalis Pharmaceuticals in US$80.5 Million Underwritten Public Offering

Latham & Watkins LLP advised Zentalis Pharmaceuticals, Inc. in its recent underwritten public offering, which is expected to generate approximately US$80.5 million in gross proceeds. The offering involved 23,000,000 shares of common stock at US$3.50 per share, with an option for underwriters to purchase …

Connect Biopharma (CNTB) investor Wei Zheng discloses 4% beneficial stake

Connect Biopharma Holdings Ltd (CNTB) investor Wei Zheng has filed an amended Schedule 13G, disclosing a beneficial ownership of 2,520,359 ordinary shares, which represents a 4% stake in the company. Zheng holds sole voting and dispositive power over these shares, with the percentage based …

Solas Capital Management (FENC) reports 1.89M Fennec shares, a 5.4% ownership stake

Solas Capital Management, LLC and Frederick Tucker Golden have reported beneficial ownership of 1,889,366 common shares of Fennec Pharmaceuticals Inc. (FENC), representing a 5.4% stake in the company. This disclosure was made via a SCHEDULE 13G/A filing. The ownership is held through a private …

Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $256.00 Price Target at Wells Fargo & Company

Wells Fargo & Company has lowered its price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) from $316.00 to $256.00, while maintaining an "equal weight" rating. This adjustment implies a potential upside of 14.71% from the stock's previous close. Despite this reduction and similar moves by other …

GT Biopharma Q2 Results: Net Loss Falls To $4.5 Million

GT Biopharma (NASDAQ: GTBP) reported a Q2 2026 net loss of $4.5 million, a significant improvement from the $30.2 million loss in Q2 2025, primarily due to the absence of a non-recurring $28.7 million Greenshoe liability from the prior year. However, operational losses widened …

ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Down on Disappointing Earnings

Theravance Biopharma (TBPH) investor group reports 17.7% beneficial stake

An investor group led by Madison Avenue International LP has reported a 17.7% beneficial stake in Theravance Biopharma, Inc. (TBPH) as of June 30, 2026. This ownership, comprising 9,212,252 Ordinary Shares, is based on 51,918,754 outstanding shares as of July 31, 2026. The group, …

Armistice Capital (IRWD) discloses 13.9M-share Ironwood Pharmaceuticals stake

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 13,932,000 shares of Ironwood Pharmaceuticals, Inc.'s Class A common stock, which represents 8.43% of the outstanding class as of June 30, 2026. This stake is held by Armistice Capital Master Fund Ltd., …

Zenas BioPharma's (ZBIO) Buy Rating Reaffirmed at Guggenheim

Guggenheim reaffirmed its "buy" rating for Zenas BioPharma (ZBIO) with a $55 price target, despite the company reporting weaker-than-expected quarterly results, including an EPS loss of $1.77 and revenue of $1 million. Analyst sentiment for ZBIO remains generally positive with a "Moderate Buy" consensus …

Estrella Immunopharma (ESLA): Armistice Capital discloses 4.99% ownership stake

Armistice Capital, LLC and Steven Boyd have disclosed a 4.99% beneficial ownership stake in Estrella Immunopharma, Inc. (ESLA) common stock. This translates to 2,051,409 shares, over which they hold shared voting and dispositive power. The shares are held by Armistice Capital Master Fund Ltd., …

Earnings call transcript: Lantern Pharma posts q2 2026 loss miss as stock slips

Lantern Pharma reported a wider-than-expected Q2 2026 net loss of $0.57 per share, primarily due to $3.6 million in non-cash warrant expenses, despite a 25% reduction in operating expenses and significant advancements in its clinical programs. The company also announced the establishment of Open-Medicine …

Armistice Capital (RIGL) reports 1.67M Rigel Pharmaceuticals shares in 13G/A

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 1,672,000 shares of Rigel Pharmaceuticals (RIGL) common stock through a Schedule 13G/A filing. This represents 8.95% of the outstanding common stock as of June 30, 2026. The shares are held by Armistice Capital …

Quoin Q2 Loss Widens; Gets FDA's Conditional Nod For QYLEKI Brand Name For QRX003

(RTTNews) - Quoin Pharmaceuticals Ltd. (QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, reported second-quarter 2026 results and provided a corporate update highlighting progress across its QRX003 and QRX009 platforms. Quoin is developing topical therapies for rare dermatologic conditions, …

Orchid Pharma Limited: Revenue and Earnings Analysts Forecasts Revisions | OCP | US68572Y1183

Eton Pharmaceuticals (NASDAQ:ETON) Sets New 1-Year High Following Earnings Beat

Eton Pharmaceuticals (NASDAQ:ETON) reached a new 52-week high after reporting strong Q2 earnings, with EPS of $0.43 and revenue of $37.59 million, significantly beating analyst estimates. The stock surged 42%, supported by a maintained "Buy" rating and increased price targets from analysts like HC …

CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains

CorMedix Therapeutics CRMD delivered second-quarter 2026 adjusted earnings of 29 cents per share, which increased 4% year over year from 28 cents reported in the year-ago quarter. The reported figure beat the Zacks Consensus Estimate of 26 cents. Consolidated revenues were $101.9 million, which …

Eton Pharmaceuticals stock hits all-time high at 55.07 USD

Eton Pharmaceuticals Inc. stock reached an all-time high of $55.07, currently trading at $54.43, significantly above its 52-week high. Despite appearing overvalued by InvestingPro analysis, the company has seen a 139.44% appreciation over the last year, with its market capitalization at $1.12 billion and …

Innate Pharma (IPHA) plans August 14, 2026 conference call and webcast

Innate Pharma S.A. (IPHA) announced it will host a conference call and live webcast on August 14, 2026, at 2:00 p.m. CEST / 8:00 a.m. EDT. The event will feature key executives, including CEO Jonathan Dickinson, and will cover the company's progress as a …

Processa Pharmaceuticals shareholders approve incentive plan amendment at annual meeting

Processa Pharmaceuticals shareholders approved several key proposals at their 2026 annual meeting on July 30, including an amendment to the 2019 Omnibus Incentive Plan to increase shares available for issuance by 200,000. Additionally, all six directors were re-elected, Cherry Bekaert, LLP was ratified as …

Vertex Pharmaceuticals: I Was Wrong About Its Near-Term Prospects (Rating Upgrade)

Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is BioMarin Pharmaceutical (BMRN) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector …

Quantum Biopharma Ltd. (CN:QNTM) Shares Decline as Biotech Uncertainty, Funding Risks and Clinical Development Challenges Pressure Investor Sentiment

Zenas BioPharma's (ZBIO) Outperform Rating Reiterated at Wedbush

Wedbush reiterated its "outperform" rating on Zenas BioPharma (NASDAQ:ZBIO) with a $45 price target, indicating a potential 54.11% upside. Despite this positive analyst sentiment, the company reported a significant miss on its quarterly earnings and revenue estimates. Other analysts have also adjusted their ratings, …

Avoro Capital discloses 9.64% Arrowhead Pharmaceuticals (ARWR) stake including warrants

Avoro Capital Advisors LLC and its controlling person Behzad Aghazadeh have disclosed a beneficial ownership of 9.64% in Arrowhead Pharmaceuticals (ARWR). This stake includes 13,823,383 shares of Common Stock, of which 2,467,828 shares are issuable upon the exercise of warrants. The investment firm holds …

Crinetics Pharmaceuticals merger with Vertex Pharmaceuticals advances after regulatory clearances

The proposed merger between Crinetics Pharmaceuticals (NASDAQ:CRNX) and Vertex Pharmaceuticals (NASDAQ:VRTX) has progressed after securing regulatory clearances, including the expiration of the Hart-Scott-Rodino Antitrust Improvements Act waiting period and approvals in Austria, Germany, and Australia. The acquisition, valued at approximately $10 billion, is expected …

Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Office is Investigating Claims on Your Behalf

Grabar Law Office is investigating potential breaches of fiduciary duty by officers and directors of ARS Pharmaceuticals, Inc., Bloom Energy Corporation, Erasca, Inc., and Insulet Corporation. The investigations concern various allegations including misleading statements regarding product timelines, supply chain reliance, and manufacturing issues, which …

RIGL Maintained by HC Wainwright & Co. -- Price Target Raised to $85

HC Wainwright & Co. maintained a "Buy" rating for Rigel Pharmaceuticals (RIGL), increasing its price target from $57.00 to $85.00, reflecting confidence in the company's future growth. Despite this, Rigel Pharmaceuticals is currently priced at $42.10, which is 56.7% overvalued compared to its GF …

Form 8K Lantern Pharma Inc For: 14 August By Investing.com

This article reports on the filing of a Form 8K by Lantern Pharma Inc. on August 14th. It is a brief announcement indicating a regulatory filing, without providing further details about the content of the 8K. The article is from Investing.com and is dated …